Viromed Medical AG
Viromed Medical AG is a pharmaceutical company focused on the development and commercialization of innovative medical products, primarily in the healthcare sector.
Business. Viromed Medical AG is a pharmaceutical company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in Germany and is primarily listed on the Xetra exchange under the ticker symbol VMEN.DE. Specific details regarding operating segments and geographic revenue mix are not disclosed.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Viromed Medical AG is a pharmaceutical company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in Germany and is primarily listed on the Xetra exchange under the ticker symbol VMEN.DE. Specific details regarding operating segments and geographic revenue mix are not disclosed.
Viromed Medical AG has a basic and diluted share count of 20.25 million shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available for Viromed, as the valuation snapshot does not provide data on return on invested capital (ROIC), gross margins, or operating margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians.
The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is unclear whether Viromed's operations are diversified or concentrated in specific markets or product lines.
Growth trajectory is also indeterminate, as the outlook for the current and next fiscal years does not include numeric deltas or revenue projections. Analysts have provided a mean price target of 10.00 EUR, with a median and high target also at 10.00 EUR, and a low target of 10.00 EUR, suggesting a consensus view with no strong buy or hold recommendations.
Risk factors include the unassessed liquidity risk and the lack of detailed financial disclosures. The company has a low dilution potential, but the absence of balance-sheet data limits the ability to evaluate credit risk or liquidity risk in detail.
Recent events and filings do not provide additional insight into the company's operations or strategic direction. The lack of detailed financial disclosures and the absence of analyst recommendations beyond a single buy rating suggest limited visibility into Viromed's near-term prospects.
- Viromed Medical AG has no immediate dilution pressure, with basic and diluted shares outstanding aligned at 20.25 million.
- Analysts have provided a mean price target of 10.00 EUR, with no strong buy or hold recommendations.
- The company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- Profitability and return metrics are not available, making it difficult to compare Viromed's performance against industry benchmarks.
- Revenue concentration and geographic exposure are not disclosed, limiting visibility into the company's operational diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income −22,6% YoY; Net income −105,0% YoY.
- ▍Operating income −22,6% YoY
- ▍Net income −105,0% YoY
Operating income −123,7% YoY; Net income +31,3% YoY.
- ▍Operating income −123,7% YoY
- ▍Net income +31,3% YoY
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Viromed Medical AG Market data — financials · 2026-05-29
- Viromed Medical AG Market data — analyst estimates · 2026-05-29